替吉奥联合奥沙利铂治疗晚期胃癌的临床研究  

A clinical study of combination chemotherapy with S-1 and oxaliplatin in patients with metastatic or recurrent gastric cancer

作　　者：覃慕萍[1] 谢杰雄[1] 李伟卓[1] 崔娟[1] 

机构地区：[1]广西梧州市红十字会医院化疗一科,543002

出　　处：《中国医疗前沿》2013年第8期69-70,共2页China Healthcare Innovation

摘　　要：目的观察替吉奥(S-1)联合奥沙利铂(oxaliplatin,L-OHP)方案治疗晚期胃癌的近期疗效及毒性反应。方法 23例均经病理组织学确诊为晚期胃腺癌,且手术不可切除或术后复发、转移胃癌。替吉奥80mg/m2/d,第1-14d,早晚饭后口服各1次;L-OHP130mg/m2加入5%葡萄糖液250ml中静脉滴注2h,第1 d,每3-4周为1个周期,完成2周期化疗后评价疗效及毒性反应。结果 23例患者有1例CR(4.3%),12例PR(52.2%),6例SD(26.1%),4例PD(17.4%),有效率(CR+PR)56.5%,疾病控制率(CR+PR+SD)82.6%。中位疾病进展时间(time to progression,TTP)5.8个月。毒副反应轻微,主要为胃肠道反应、骨髓抑制及外周神经毒性反应,但主要为Ⅰ-Ⅱ度。结论替吉奥联合奥沙利铂方案治疗晚期胃癌有较好疗效,毒副反应轻微,患者耐受性好,可作为晚期胃癌化疗方案临床应用推广。Objective To evaluate the short term efficacy and toxicity of S-1 in combination with oxaliplatin in the patients with metastatic or recurrent gastric cancer. Methods 23 patients with metastatic or recurrent adenocarcinoma of the stomach were enrolled. S-1 was administered orally twice daily on days 1-14 at a dose of 80 mg/m2/day, and oxaliplatin was administered intravenously at a dose of 130 mg/m2 on day 1, repeated every three or four weeks. Efficacy and toxicity would be evaluated after the completion of two cycles of chemotherapy. Results Complete response was observed in 1 patients（4.3%）, and partial remission was observed in 12 patients（52.2%）, 6 patients achieved a stable status（26.1%）, 4 patients suffered from progressive disease（17.4%）. The total response rate（CR＋PR） was 56.5% and the disease control rate（CR＋PR＋SD） was 82.6%. Median time to progression（TTP） was 5.8 months. Gastrointestinal reaction, peripheral nerve toxictity and hematological toxicities were the predominant toxicities. Most toxicities were I / 1I grade and mild. Conclusion The combination of S-1 and oxaliplatin as treament for patients with metastatic or recurrent gastric cancer was highly effective and well tolerated,which merits the further study in a prospective clinical trial.

关 键 词：胃癌 替吉奥 奥沙利铂 化疗 

分 类 号：R735.2[医药卫生—肿瘤]